Research Article
Efficacy of Trastuzumab + Cisplatin Combined with Irinotecan on the Quality of Life of Patients with Advanced Her-2 Positive Gastric Cancer
Table 1
Comparison of general information of the two groups of patients (n = 60).
| | Control group | Joint group | X2/t | |
| Age (years) | 59.86 ± 4.72 | 60.14 ± 5.03 | 0.314 | 0.754 | Male/female | 41/19 | 38/22 | 0.333 | 0.564 | TNM staging |
| IIIa | 15 (25) | 14 (23.33) | 0.046 | 0.831 | IIIb | 21 (35) | 20 (33.33) | 0.037 | 0.847 | IV | 24 (40) | 26 (43.33) | 0.137 | 0.711 | Disease site |
| Fundus of stomach | 26 (43.33) | 25 (41.67) | 0.034 | 0.853 | Gastric antrum | 23 (38.33) | 25 (41.67) | 0.139 | 0.709 | Cardia | 11 (18.33) | 10 (16.67) | 0.058 | 0.810 | Tumor typing |
| Poorly differentiated diffuse carcinoma | 27 (45) | 25 (41.67) | 0.136 | 0.713 | Moderately differentiated adenocarcinoma | 15 (25) | 16 (26.67) | 0.044 | 0.835 | Poorly differentiated adenocarcinoma | 13 (21.67) | 12 (20) | 0.051 | 0.822 | Hepatoid adenocarcinoma | 3 (5) | 4 (6.67) | 0.152 | 0.697 | Mucinous adenocarcinoma | 2 (3.33) | 3 (5) | 0.209 | 0.648 |
|
|